➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Baxter
McKesson
Boehringer Ingelheim
Mallinckrodt

Last Updated: September 21, 2020

DrugPatentWatch Database Preview

Patent: 6,399,587

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,399,587
Title: Recombinant adenoviral vectors comprising a splicing sequence
Abstract:The invention concerns a recombinant adenoviral vector driving from an adenovirus genome at least by deleting all or part of the E1 region, the adenoviral vector comprising an expression cassette of a gene of interest placed under the control of elements necessary for its expression in a host cell or a host organism, the elements required for its expression including at least a splicing sequence. The invention is characterized in that the splicing sequence is derived from a eukaryotic nuclear gene selected among the ovalbumen genes, .beta. or .beta.-globine, collagen and factor VIII of mammals or a synthetic splicing sequence. The invention also concerns a host cell and an infectious viral particle comprising such a vector, a method for preparing such a particle and their therapeutic or prophylactic use. The invention further concerns a pharmaceutical composition containing the adenoviral vector, the host cell or the viral particle.
Inventor(s): Mehtali; Majid (Graffenstaden, FR), Leroy; Pierre (Strasbourg, FR), Michou; Anne-Isabelle (Vienna, AT)
Assignee: Transgene S.A. (Strasbourg, FR)
Application Number:09/445,093
Patent Claims:see list of patent claims

Details for Patent 6,399,587

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Transgene S.A. (Strasbourg, FR) 2017-06-02 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Transgene S.A. (Strasbourg, FR) 2017-06-02 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Transgene S.A. (Strasbourg, FR) 2017-06-02 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Mallinckrodt
Baxter
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.